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Abstract
Context: Several studies suggest that body composition (ie, body proportions of muscle
and fat defined by computed tomography) is associatedwith clinical outcomes of several
cancer types, including renal cell cancer (RCC).
Objective: To conduct a systematic review and meta-analysis of the evidence on body
composition in relation to clinical outcomes in RCC.
Evidence acquisition: Literaturewas reviewed through October 2016 using PubMed and
Embase. We included studies investigating computed tomography-measured cross-
sectional areas of visceral adipose tissue (VAT), perinephric fat, subcutaneous adipose
tissue (SAT), skeletal muscle index (SMI), and skeletal muscle radiodensity (SMD) in
relation to perioperative outcomes, treatment toxicity, and survival in RCC patients.
Evidence synthesis: We included 28 studies with a total of 6608 patients. Binary
classification of body composition was used in most studies. In metastatic RCC (mRCC)
patients treated with antiangiogenic drugs, dose-limiting toxicity was more frequent in
patients with low versus high SMI (four studies, risk difference = 16%, 95% confidence
interval [CI]: 2–31%, p = 0.03, I2 = 26%). Low versus high SMI (six studies, hazard ratio =
1.48, 95% CI: 1.08–2.03, p = 0.02, I2 = 28%) and SMD (four studies, HR = 1.56, 95% CI: 1.20–
2.03, p = 0.0008, I2 = 0%) were associated with an increased risk of overall mortality in
mRCC. Low versus high VAT and perinephric fat were not consistently associated with
perioperative outcomes and survival. No associations for SAT were found.
Conclusions: Low SMI is associated with increased dose-limiting toxicity, and low SMI
and SMD are associated with increased overall mortality in mRCC. The association of
VAT, perinephric fat, and SAT with clinical outcomes needs further investigation, also in
localized RCC.
Patient summary: We reviewed studies assessing the association of body composition
with clinical outcomes in renal cell cancer.We demonstrated higher risk of dose-limiting
toxicity and overall mortality for metastatic renal cell cancer patients with low versus
high skeletal muscle index or skeletal muscle radiodensity, but observed inconsistent
associations with visceral adipose tissue and perinephric fat.
# 2016 European Association of Urology. Published by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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1. Introduction
Renal cell carcinoma (RCC) is the most common type of
kidney cancer. At time of diagnosis, 70–80% of RCC patients
have localized disease and the remaining 20–30% have
metastatic disease [1]. Almost all RCC patients with
localized disease are treated with partial or radical
nephrectomy [2], but 10–20% of them will have a relapse
and developmetastatic RCC (mRCC) [3]. Treatment of mRCC
mainly consists of antiangiogenic drugs, sometimes pre-
ceded by debulking surgery [2]. Five-yr survival rates vary
between approximately 90% (Stage I disease) and 10%
(Stage IV disease) [4].
For outcomes of RCC, several prognostic classification
systems exist. Prediction of perioperative outcomes follow-
ing partial nephrectomy is currently based on anatomic
classification systems (eg, PADUA, RENAL) [2]. In localized
RCC, the University of California, Los Angeles Integrated
Staging System (UISS) score and the Stage Size Grade and
Necrosis score are predictive of survival (SSIGN) [2]. For
mRCC, the Memorial Sloan Kettering Cancer Center
(MSKCC) score and the Heng score are the most widely
used prognostic scores [2]. The presence of unexplained
variation in these prognostic models [2], as well as the fact
that factors predicting antiangiogenic drug-related toxicity
in mRCC are relatively unknown [5], has fueled the pursuit
of novel prognostic factors, including body composition.
Body composition refers to the amount and distribution
of lean tissue, adipose tissue, and bone in the human body.
Lean tissue mainly consists of skeletal muscle (SM) while
adipose tissue includes visceral (VAT), subcutaneous (SAT),
and intermuscular adipose tissue. Part of the VAT is located
between Gerota’s fascia and the renal capsule (perinephric
fat). Cross-sectional area and radiodensity of these tissues
can be assessed by analysis of computed tomography (CT)
scans taken in routine cancer care using predetermined
Hounsfield Unit ranges for each tissue [6,7].
Body composition features may be associated with
perioperative outcomes, treatment toxicity, and survival
outcomes in RCC patients in several ways. For example,
excess VAT and/or perinephric fat may reduce the operative
visual field and operating space and hamper the dissection
of perinephric fat off the renal capsule [8,9]. VAT also
produces numerous growth factors, angiogenic factors, and
adipokines, which have proinflammatory and protumori-
genic properties and may negatively influence clinical
outcomes [10]. Low SM radiodensity (SMD) is related to
high muscle lipid content and to a propensity for
postoperative inflammation [11]. Low SM mass may be
associated with increased risk of toxicity of antiangiogenic
drugs due to the administration of a fixed drug dose,
resulting in a higher dose per kg lean tissue [12]. Severe
overall depletion of SM and/or adipose tissue (cachexia) has
for a very long time been associated with morbidity and
mortality [13].
In this systematic review, we aim to evaluate the
association of CT-measured VAT, perinephric fat, SAT, SM,
and SMD with perioperative outcomes, treatment toxicity,
and survival outcomes in RCC patients.
2. Evidence acquisition
2.1. Search strategy
PubMed and Embase databases were searched for studies
indexed from database inception to October 2016 with the
assistance of a professional librarian. We used a combina-
tion of MeSH and Emtree terms and related keywords in
titles and abstracts. Search terms combined patient-related
terms (eg, kidney or renal cell cancer), body composition
terms (eg, adipose tissue, perinephric fat, andmusclemass),
and clinical outcomes (eg, perioperative outcomes, toxicity,
recurrence, progression, and mortality; Supplementary
data). We followed the Preferred Reporting Items for
Systematic Reviews and Meta-analyses criteria (Fig. 1)
[14] for evaluating records identified during the literature
search. The search was limited to articles written in the
English language, and publications from conferences were
excluded. Reference lists of relevant articles were also
checked. Two investigators (A.V. and N.K.) screened all
retrieved references independently, and discordant deci-
sions were discussed and resolved.
2.2. Study selection, data extraction, and quality assessment
Articles were considered relevant if they reported on
original studies in RCC patients with respect to CT-
measured body composition in relation to clinical out-
comes. Reviews, editorials, and commentaries, as well as
studies that did not measure body composition based on CT
scans or did not report on relevant outcomes, were checked
for relevant references but were excluded from this review.
Information extracted included the first author, year of
publication, country, study population (number of patients
and outcomes, tumor stage, and/or type of nephrectomy),
follow-up time, timing of CT scan, anatomical level of
analysis (eg, third lumbar vertebra [L3], umbilicus), image
software used, tissue type with continuous or cut-off values
used, outcome, risk estimates with 95% confidence intervals
(95% CI) or p values or means or medians or percentages,
and factors that were adjusted for in the analysis. When
necessary, authors were contacted for additional data.
The quality of the included articles was assessed by one
author (A.V.) using the Newcastle-Ottawa Scale for cohort
studies (Table 1) [15]. Key quality areas assessed included:
(1) selection of study groups, (2) comparability of the
groups, (3) assessment of the outcome. The operationaliza-
tion of these quality areas is summarized in the footnote of
Table 1. A total score of 5 or less was considered low, 6 or
7 was considered moderate, and 8 or 9 was deemed high
quality.
2.3. Data synthesis
Data were synthesized for localized and metastatic disease,
separately. Meta-analysis was performed using Review
Manager 5.3 (The Cochrane Collaboration, Copenhagen,
Denmark). We used the Mantel-Haenszel test for meta-
analysis of risk differences. The inverse variance technique
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was used for meta-analysis of hazard ratios. Due to the
clinical heterogeneity inherent in our data, random-effects
models were used for all meta-analyses. Statistical hetero-
geneity was assessed with I2 values. Publication bias was
evaluated using funnel plots. When no meta-analysis could
be performed, we described the study results.
3. Results
3.1. Search outcome
Twenty-eight studies matched the selection criteria (Fig. 1,
Table 1) [5,8,9,16–40], including a total of 6608 patients.
Eleven studies concerned perioperative outcomes (Table 2)
[8,9,16–24], four studies concerned treatment toxicity
(Table 3) [5,25–27], and 16 studies concerned recurrence,
progression, and/or mortality (Table 4) [21,23,27–40].
3.2. Quality assessment
Study characteristics and quality are summarized in
Table 1. All but four studies [16,25,26,31] were single
center historical cohort studies. Nineteen studies included a
consecutive series of patients while nine studies did not
report this [27,28,30,33–35,39] or included participants of a
clinical trial [25,31]. Fourteen studies had more than 90%
completeness of CT scans, while 14 studies did not report
this [16,28,33] or had less than 90% completeness
[5,9,18,21,26,27,30,32,38–40].
The level of L3 is the preferred method for body
composition analysis since cross-sectional areas at L3 are
linearly related to whole body mass of SM, VAT, and SAT
(Fig. 2) [6,7,41]. L3 was selected in all 10 studies investi-
gating SM cross-sectional areas normalized for height in m2
(SM index, SMI) [5,21,25–28,31,35,37–39] or SMD
[31,35,38]. One study was limited to a single muscle
(psoas) [23] which is not reflective of SM. For adipose
tissues, only three out of 14 studies used L3 as the landmark
image [28,31,35]. Eight studies assessed cross-sectional
area of VAT [8,22,29,30,32–34,36] or SAT [29,30,33] at the
level of the umbilicus, which has also been related to whole
body mass of VAT and SAT [42]. However, the umbilicus is a
soft tissue landmark and subject to more variability than
the bony landmark L3. Some studies only assessed the linear
thickness of VAT [9], perinephric fat [9,16–19,24], and SAT
[9,18,19,24].
In most investigations, continuous data (eg, cross-
sectional area, index, or radiodensity) were converted to
binary data for the main analysis (eg, low vs high).
Therefore, some of the variation in methodology is likely
to be less important (eg, categorization of low vs high VAT at
either L3 or umbilicus would be expected to give largely
[(Fig._1)TD$FIG]
Records identified through database 
searching 
(n = 1554) 
Additional records identified through 
other sources 
(n = 0) 
Records after duplicates removed 
(n = 1008) 
Abstracts screened 
(n = 71) 
Records excluded after 
screening title (n = 937) 
Full-text articles assessed for 
eligibility 
(n = 39) 
Full-text articles excluded, 
with reasons (n = 11) 
-  No relevant outcomes (n = 3)   
-  No CT measurement 
perinephric fat (n = 6) or 
body composition (n = 1) 
related to outcomes 
Commentaries - (n = 1)
Studies included in qualitative 
synthesis 
(n = 28) 
Records excluded with 
reasons (n = 32) 
-  Reviews (n = 13)  
-  Editorials and 
commentaries (n = 4) 
-  Not relevant (n = 15) 
Fig. 1 – Flow diagram for study inclusion.
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Table 1 – Summary of the quality of the included studies based on the Newcastle-Ottawa Quality Assessment Scalea
First author,
yr, (ref)
N Study
design
Ethnicity Representa-
tiveness
exposed
cohort (1)
Selection
non-exposed
cohort (2)
Ascertainment
of exposure
(3)
Demonstration
outcome not
present at
start study
(4)
Comparability
of cohorts on
the basis of the
design or
analysis, A (5)
Comparability
of cohorts on
the basis of
the design or
analysis, B (6)
Assessment
of outcome
(7)
Was follow-up
long enough
for outcomes
to occur (8)
Adequacy
of follow-up
of cohorts (9)
Total
score
Perioperative outcomes
Hagiwara, 2012, Japan [8] 121 SHC Asian 1 1 0 0 1 NA 1 1 1 6/8
Okhunov, 2012, USA [16] 250 MHC Caucasian 0 1 0 0 1 0 1 1 0 4/9
Akaihata, 2013, Japan [17] 95 SHC Asian 1 1 0 0 0 NA 1 1 1 5/8
Gorin, 2013, USA [18] 195 SHC Caucasian 0 1 0 0 1 1 1 1 1 6/9
Ioffe, 2013, USA [9] 118 SHC Caucasian 0 1 0 0 1 1 1 1 0 5/9
Macleod, 2014, USA [19] 53 SHC Caucasian 1 1 0 0 1 1 1 1 0 6/9
Zheng, 2014, USA [20] 41 SHC Caucasian 1 1 0 0 0 0 1 1 0 4/9
Sharma, 2015, USA [21] 93 SHC Caucasian 0 1 1 0 1 NA 1 1 1 6/8
Yuge, 2015, Japan [22] 167 SHC Asian 1 1 0 0 1 NA 1 1 0 5/8
Peyton, 2016, USA [23] 128 SHC Caucasian 1 1 0 0 0 NA 1 1 0 4/8
Raman, 2016, USA [24] 240 SHC Caucasian 1 1 0 0 0 0 1 1 0 4/9
Treatment toxicity
Antoun, 2010, France [25] 55 ClT Caucasian 0 1 1 1 NA NA 1 1 1 6/7
Huillard, 2013, France [5] 61 SHC Caucasian 0 1 1 0 NA NA 1 1 1 5/7
Cushen, 2014, Ireland [26] 55 MHC Caucasian 0 1 0 0 NA NA 1 1 1 4/7
Ishihara, 2016, Japan [27] 71 SHC Asian 0 1 1 0 NA NA 1 1 1 5/7
Prognosis
Naya, 2010, Japan [28] 117 SHC Asian 0 1 0 0 1 1 1 0 0 4/9
Ladoire, 2011, France [29] 105 SHC Caucasian 1 1 0 0 1 1 1 1 0 6/9
Steffens, 2011,
Germany [30]
77 SHC Caucasian 0 1 0 0 1 1 1 0 0 4/9
Antoun, 2013, France [31] 142 ClT Caucasian 0 1 1 1 1 1 1 0 0 6/9
Kaneko, 2014, Japan [32] 285 SHC Asian 0 1 0 0 1 0 1 0 0 3/9
Mano, 2014, USA [33] 201 SHC Caucasian 0 1 0 0 0 0 1 0 0 2/9
Park, 2014, Korea [34] 706 SHC Asian 0 1 0 0 1 1 1 0 0 4/9
Gu, 2015, China [35] 124 SHC Asian 0 1 1 0 1 1 1 1 0 6/9
Lee, 2015, Korea [36] 2187 SHC Asian 1 1 1 0 1 0 1 0 0 5/9
Psutka, 2015, USA [37] 387 SHC Caucasian 1 1 1 0 1 1 1 1 0 7/9
Sharma, 2015, USA [21] 93 SHC Caucasian 0 1 1 0 1 1 1 0 1 6/9
Peyton, 2016, USA [23] 128 SHC Caucasian 1 1 0 0 0 0 1 0 0 3/9
Fukushima, 2016,
Japan [38]
92 SHC Asian 0 1 1 0 1 1 1 0 0 5/9
Fukushima, 2016,
Japan [39]
37 SHC Asian 0 1 1 0 1 0 1 1 0 5/9
Ishihara, 2016,
Japan [27]
71 SHC Asian 0 1 1 0 1 1 1 0 0 5/9
Thiel, 2016, USA [40] 405 SHC Caucasian 0 1 0 0 1 1 1 0 0 4/9
ClT = clinical trial participants; MHC = multi-center historical cohort; NA = not applicable; ref = reference; SHC = single center historical cohort.
a Key quality criteria that were assessed included: (1) representativeness of the exposed cohort (ie, consecutive series and  90% available computed tomography [CT] scans or comparison with population without CT
scans), (2) selection of the nonexposed cohort (ie, drawn from the same community as the exposed cohort), (3) assessment of the exposure (ie, CT-assessed body composition [cross-sectional area or radiodensity] and
use of sex-specific cut-off values), (4) demonstration that the outcome (ie, renal cell carcinoma) was not present at the start of the study, (5) adjustment for tumor size or stage, (6) adjustment for a predictive score, (7) the
assessment of the outcomes of interest (ie, independent assessment or record linkage), (8) the duration of the follow-up period for outcome to occur ( 5 yr and  2 yr follow-up was considered to be adequate for recurrence,
progression, and survival outcomes in localized/advanced and metastatic renal cell carcinoma, respectively), and (9) the adequacy (ie, completeness) of the follow-up process.
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Table 2 – Studies on body composition and perioperative outcomes
First author, yr
country (ref)
Study population Timing of
CT scan
Level of analysis,
image software
used
Tissue (comparison) Outcome OR (95% CI) or b (95%
CI) or r or mean or
median or %
p value Adjustment factors
Radical nephrectomy
Hagiwara, 2012,
Japan [8]
121 cT1a-cT3a RCC patients
treated with laparoscopic
radical nephrectomy from
2006–2010
Not reported Umbilicus, standard
software
VAT ( 100 vs < 100 cm2) Operation time ( vs < mean) OR=3.70 (1.38, 9.90) BMI, sex (tumor size and
clinical T stage assessed but
not significant)
Akaihata, 2013,
Japan [17]
95 consecutive cT1-cT2 RCC
patients treated with
retroperitoneal laparoscopic
radical nephrectomy from
2004–2012
Preoperative Renal vein, software not
reported
Perinephric fat
(continuous, mm)a
Operation time (min) b = 0.252 0.016 Anteroposterior renal
diameter, sagittal
abdominal diameter, 12th
rib to iliac crest distance,
BMI
Estimated blood loss (ml) b = 0.336 0.001 Sagittal abdominal
diameter, BMI, prior
abdominal surgery
Peyton, 2016,
USA [23]
128 Stage III-IV RCC patients
treated with radical
nephrectomy from 2008–2012
(19 minor, 11 major
complications)
Preoperative (60
d prior to surgery)c
L3, Philips iSite PACS Total psoas ( vs > quartile 1;
4.271 cm2/m2 for M, 3.804 cm2/m2
for F)
Blood transfusion
 Grade II complicationsb
 Grade III complications
Estimated blood loss (mean)
Length of hospital stay (mean)
18 vs 23%
OR = 0.61 (0.16, 2.8)
OR = 4.2 (1.18, 14.8)
613 vs 809 ml
6.0 vs 4.7 d
0.81
0.49
0.15
Univariable
Yuge, 2015,
Japan [22]
167 cT1a-cT3b RCC patients
with laparoscopic radical
nephrectomy from 2006–2012,
six surgeons
Not reported Umbilicus, standard
software
VAT ( 100 vs < 100 cm2) Operation time ( vs <mean),
nonexpert surgeons
OR = 5.15 (1.68, 15.8) Clinical T stage
Operation time ( vs <mean),
expert surgeons
NS
Partial nephrectomy
Okhunov, 2012,
USA [16]
250 consecutive cT1a RCC
patients treated with
laparoscopic partial
nephrectomy or cryoablation
from 2004–2010
Preoperativec Renal hilum, standard
software
Perinephric fat (continuous, mm)d Complicationsb
Estimated blood loss (ml)
Length of hospital stay (d)
Operation time (min)
Warm ischemia time (min)
Spearman r NS
NS
NS
NS
NS
Univariable
Gorin, 2013,
USA [18]
195 RCC patients treated with
minimally invasive laparoscopic
or robot-assisted partial
nephrectomy from 2006–2012,
single surgeon
Preoperative Renal vein (PF) and
umbilicus (SAT), software
not reported
Perinephric fat (continuous, mm)e Grade I–IV complicationsb
Grade III–IV complications
Operation time (min)
Operation time (min)
OR = 1.05 (1.02, 1.09)
OR = 1.05 (1.00, 1.10)
b = 1.15 (0.44, 1.86)
b
0.002
NS
RENAL score, BMI
RENAL score
Univariable
Sex, surgical technique,
tumour diameter, RENAL
score, ASA score
Length of hospital stay (d) b NS Univariable
SAT (continuous, mm)e All above outcomes b NS Univariable
Ioffe, 2013,
USA [9]
118 RCC patients treated with
minimally invasive laparoscopic
or robot-assisted partial
nephrectomy from 2002–2011,
single surgeon
Preoperative Uncinate process of the
pancreas (VAT), umbilicus
(SAT), renal vein
(perinephric fat), software
not reported
VAT (tertile 2 vs 1 cm)f
VAT (tertile 3 vs 1 cm)
SAT (tertile 2 vs 1 cm)f
SAT (tertile 3 vs 1 cm)
Perinephric fat (tertile 2 vs 1 cm)5
Perinephric fat (tertile 3 vs 1 cm)
VAT, SAT, Perinephric fat
VAT, SAT, Perinephric fat
Complicationsb
Operation time
Estimated blood loss
OR = 2.74 (0.79, 9.56)
OR = 1.26 (0.30, 5.34)
OR = 0.45 (0.12, 1.70)
OR = 0.62 (0.16, 2.36)
OR = 0.51 (0.14, 1.88)
OR = 0.65 (0.18, 2.30)
b
b
0.11
0.76
0.24
0.49
0.31
0.50
NS
NS
Age, race, sex, RENAL score,
Charlson Comorbidity
Index, types of fat
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Table 2 (Continued )
First author, yr
country (ref)
Study population Timing of
CT scan
Level of analysis,
image software
used
Tissue (comparison) Outcome OR (95% CI) or b (95%
CI) or r or mean or
median or %
p value Adjustment factors
Macleod, 2014,
USA [19]
53 consecutive RCC patients
treated with robot-assisted
partial nephrectomy from
2009–2013
Preoperative
(nearest to date of
surgery)c
Renal vein, GE Centricity
PACS 3.0
SAT (continuous, mm)g
Perinephric fat (continuous, mm)g
Operation time (min)
Estimated blood loss (ml)
Operation time (min)
Estimated blood loss (ml)
b=-0.53 (-1.2, 0.15)
b = 3.0 (6.4, 0.37)
b = 1.2 (0.5, 1.9)
b = 6.9 (3.6, 10)
NS
NS
<0.05
<0.05
Age, sex, tumour laterality,
RENAL score, body mass
index, ASA score, history of
abdominal surgery
Zheng, 2014,
USA [20]
41 consecutive RCC patients
treated with open partial
nephrectomy from 2011–2013
Preoperative (90
d prior to surgery)
Renal hilum, Image J Perinephric fat (surface density
pixel unit)h
Operation time (h)
Estimated blood loss (ml)
Warm ischemia time (min)
Perioperative fat dissection
difficulty
Pearson r = 0.31
Pearson r = 0.12
Pearson r = 0.10
OR = 1.001 (1.000,
1.001)
0.04
0.44
0.53
0.01
Univariable
Sex, estimated blood loss
Sharma, 2015,
USA [21]
93 mRCC patients treated with
cytoreductive nephrectomy
from 2001–2014
Preoperative (90
d prior to surgery)c
L3, AW Server Software SMI (< vs 43 cm2/m2 for M with
BMI < 25,  53 for M with BMI >
25,  41 for F)
Blood transfusion
Grade II complicationsb
Grade IIIa complications
Estimated blood loss (median)
Length of hospital stay (median)
74.1 vs 42.4%
33.3 vs 25.8%
11.1 vs 12.1%
700 vs 500 ml
6 vs 5 d
0.006
1.00
0.42
0.02
Univariable
Raman, 2016,
USA [24]
240 RCC patients treated with
robot-assisted partial
nephrectomy from 2010–2015
Preoperative Renal vein (PF) and
umbilicus (SAT), software
not reported
Perinephric fat (continuous)i
Perinephric fat:SAT ratio
(continuous)i
Operation time (min)
Ischemia time (min)
Estimated blood loss (ml)
Length of stay (d)
Complicationsb
Operation time (min)
Ischemia time (min)
Estimated blood loss (ml)
Length of stay (d)
Complicationsb
Pearson r = 0.26
Pearson r = 0.03
Pearson r = 0.06
Pearson r = 0.01
OR = 1.07 (0.84, 1.36)
Pearson r = 0.33
Pearson r = 0.04
Pearson r = 0.06
Pearson r = 0.91
OR = 1.82 (1.10, 3.01)
0.001
0.71
0.46
0.87
<0.0001
0.61
0.43
0.91
Univariable
Univariable
ASA = American Society of Anesthesiologists physical status classification; BMI = body mass index; CI = confidence interval; F = female; L3 = third lumbar vertebra; M = male; NS = nonsignificant; OR = odds ratio;
ref = reference; SAT = subcutaneous adipose tissue; SMI = skeletal muscle index; VAT = visceral adipose tissue.
a Perinephric fat distance measured as the distance from the anterior renal capsule to the Gerota fascia or closest overlying bowel, at the midpoint of the main renal vein entering the hilum.
b Complications were classified according to the Clavien Classification.
c Both CT and MRI scans were used.
d Perinephric fat thickness measured as the perpendicular distance between the kidney’s posterior surface and the external margin of iliopsoas at the level of the renal hilum.
e Perinephric fat thickness measured as the distance between the abdominal wall and the posterior renal capsule at the level of the renal vein; SAT thickness defined as the distance between the skin and the abdominal wall
at the level of the umbilicus.
f VAT thickness defined as the anterior-posterior diameter from the anterior abdominal wall to the superior mesenteric vein at the level of the uncinate process of the pancreas; SAT thickness defined as the largest anterior-
posterior distance between the skin and the anterior abdominal wall at the level of the umbilicus; Perinephric fat thickness measured at the level of the renal vein, subtracting the diameter of the kidney from the Gerota’s
fascia measurement.
g SAT thickness defined as the distance between the skin and the body musculature at the level of the renal vein and the sum of four subcutaneous measurements was taken (anterior, posterior, posterolateral and posterior);
Perinephric fat thickness measured by Eisner method (sum of anterior, posterior, medial, lateral).
h Perinephric fat surface density measured at the level of the renal hilum on the ipsilateral side of the kidney harboring the suspected renal tumor, based on Hounsfeld Units.
i Perinephric fat thickness measured by subtracting the anteroposterior diameter of the kidney from the anteroposterior diameter of the perinephric space at the level of the renal vein; SAT thickness measured as the greatest
anteroposterior distance from the skin to anterior abdominal wall at the level of the umbilicus.
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similar results). Sex-specific cut-off values deserve consid-
eration, as men are known to have higher VAT, lower SAT,
and higher SM mass compared with women [43]. Sex-
specific cut-off values were used in or could be retrieved for
all studies assessing SM [5,21,25–27,31,35,37–39] or total
psoas [23] but only four studies assessing VAT [31,33,35,36]
or SAT [31]. Six studies additionally used body mass index
(BMI)-specific cut-off points for SMI [5,21,25,27,38,39],
accounting for lower SMI with lower BMI.
All but five studies [17,20,23,24,33] adjusted their
analyses for tumor size or stage, or were restricted to one
tumor stage. Three [9,18,19] of six studies on perioperative
outcomes in patients treated with partial nephrectomy and
11 [21,27–31,34,35,37,38,40] of 16 studies on survival
outcomes adjusted their analyses for predictive scores.
Follow-up times for recurrence, progression, and mortality
ranged between 13 mo and 7.2 yr; they were 5 yr for only
one study on localized/advanced disease [37] and 2 yr for
only three studies on metastatic disease [29,35,39]. Hardly
any studies reported completeness of follow-up. Overall,
study quality was low to moderate.
3.3. Results of meta-analysis
There was sufficient evidence of consistent nature to be
subjected to meta-analysis for SMI in relation to treatment
toxicity, SMI in relation to overall mortality, and SMD in
relation to overall mortality in mRCC patients treated with
antiangiogenic agents.
3.3.1. Skeletal muscle and treatment toxicity
Four studies reporting on 242 mRCC patients treated with
sorafenib [25] or sunitinib [5,26,27] were meta-analyzed to
assess dose-limiting toxicity in patientswith lowversus high
SMI (Table 3). Dose-limiting toxicity was more frequent in
patients with low SMI with or without BMI <25 kg/m2
versus patients with high SMI or BMI >25 kg/m2 (risk
difference = 16%, 95% CI: 2–31%, p = 0.03, I2 = 26%; Fig. 3A).
3.3.2. Skeletal muscle and overall mortality
Six studies reporting on 559 mRCC patients were meta-
analyzed to assess the association of SMI with overall
mortality [21,27,31,35,38,39]. Patientswith low versus high
SMI had an increased risk of overall mortality (hazard
ratio = 1.48, 95% CI: 1.08–2.03, p = 0.02, I2 = 28%; Fig. 3B).
Four studies reporting on 429mRCC patients weremeta-
analyzed to assess the association of SMD with overall
mortality. Patients with low versus high SMD had an
increased risk of overall mortality (hazard ratio = 1.56, 95%
CI: 1.20–2.03, p = 0.0008, I2 = 0%; Fig. 3C).
3.3.3. Publication bias
We assessed publication bias using funnel plots (data not
shown).Wedid not identify any evidence of publication bias.
Table 3 – Studies on skeletal muscle index and treatment toxicity
First author, yr,
country (ref)
Study population Timing of
CT scan
Level of
analysis, image
software
used
Tissue
comparison
Outcome Results p value Adjustment
factors
Antoun, 2010,
France [25]
55 mRCC patients
treated with sorafenib
from 2003–2005
(37 M, 18 F)
Close to
treatment
initiation
L3, Slice-O-Matic Low SMIa (19 M) vs
high SMI (18 M)
DLT, % 37 vs 5.5 0.04 Univariable
Low SMI and BMI <25
kg/m2 (7 M) vs high
SMI or BMI >25 kg/m2
(30 M)
DLT, % 71 vs 10 0.002
Low SMI and BMI <25
kg/m2 (17 M+F) vs
high SMI or BMI >25
kg/m2 (38 M+F)
DLT, % 41 vs 13 0.03
Huillard, 2013,
France [5]
61 mRCC patients
treated with sunitinib
from 2006–2012
(38 M, 23 F)
1 mo before
treatment
initiation
L3, ImageJ Low SMIa and BMI <25
kg/m2 (n = 20) vs high
SMI or BMI >25 kg/m2
(n = 41)
DLT, %b 50 vs 19.5 0.01 Univariable
Cushen, 2014,
Ireland [26]
55 clear cell mRCC
patients treated with
sunitinib from 2007–
2012 (43 M, 12 F)
 1 mo of
treatment
initiation
L3, Osirix SMI, Q1 (< 44.8)
(n = 13) vs Q4 (> 63.2)
cm2/m2 (n = 14)
DLT, %c 92 vs 57 0.05 Univariable
Low SMIa (n = 18) vs
high SMI (n = 37)d
DLT, %c 77.7 vs 70 NS
Ishihara, 2016,
Japan [27]
71 mRCC patients
treated with sunitinib
from 2007–2014
(50 M, 21 F)
1 mo before
treatment
initiation
L3, Toshiba Low SMIe (n = 45) vs
high SMI (n = 26)
DLT, %b 51.1 vs 50.0 0.93 Univariable
BMI = body mass index; DLT = dose-limiting toxicity; F = female; L3 = third lumbar vertebra; M = male; mRCC = metastatic renal cell cancer; Q = quartile;
ref = reference; SD = standard deviation; SMI = skeletal muscle index.
a Sex-specific cut-off values for SMI were 55.4 cm2/m2 for males and 38.9 cm2/m2 for females.
b After one cycle.
c After four cycles.
d Data retrieved from review paper.
e Sex-specific cut-off values were 43 cm2/m2 for males with BMI <25, 53 cm2/m2 for males with BMI >25, and 41 cm2/m2 for females,
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Table 4 – Studies on body composition and renal cell cancer prognosis
First author, yr, country (ref) Study population Follow-up Timing of CT scan Level of analysis, image
software used
Tissue
(comparison)
Outcome HR (95% CI) Adjustment factors
Localized and/or advanced RCC
Naya, 2010, Japan [28] 117 male Stage I–IV ccRCC
patients (7 deaths)
Median 33.9 mo (range 3-
99.4)
Preoperative 10 cm above the L4-5
vertebral interspace, Fat
Measurement
VAT (<vs median; 75 cm2) CSM 18.4 (1.1, 309) Performance status, tumour
stage, tumour grade,
microvenous invasion,
smoking status, BMI, CRP
PN or RN from 2002–2008
Kaneko, 2014, Japan [32] 285 localized pT1-pT4 RCC
patients (29 recurrences)
Median 36.7 mo (IQR
19.5-57.7)
Preoperative (4
wk prior to
surgery)
Umbilicus, standard software VAT (< vs 120 cm2) Recurrence 1.91 (0.84, 4.36) Fuhrman grade, pT stage,
tumour size, microvascular
invasion
241 localized pT1-pT4 ccRCC
(28 recurrences)
Median 35.6 mo (IQR
19.0-55.5)
VAT (< vs 120 cm2) Recurrence 1.97 (1.52, 9.27) Age, CRP, Fuhrman grade, pT
stage, tumour size,
micovascular invasion
219 localized pT1-pT2 ccRCC VAT (< vs 120 cm2) Recurrence 4.28 (1.53, 12.0) Fuhrman grade, tumour size,
microvascular invasion
PN or RN from 2005–2011
Mano, 2014, USA [33] 201 Stage I–III ccRCC
(26 deaths from several
cancers)
surgery from 2001–2011
Median 4 y (range 0.04 –
9)
Preoperative Umbilicus, ImageJ TAT (per 100 cm2)
SAT (per 100 cm2)
VAT (per 100 cm2)
VAT% (per 10%)
VAT (< vs median; 219 cm2
for M, 156 for F)a
OM 0.83 (0.65, 1.05)
0.72 (0.50, 1.05)
0.82 (0.49, 1.36)
1.13 (0.80, 1.59)
1.39 (0.63, 3.05)
Sex
Park, 2014, Korea [34] 706 localized pT1-pT2 RCC
patients (91 recurrences)
PN or RN from 2003–2012
Median 42.0 mo (IQR 18.0,
64.0)
Preoperative Umbilicus, Rapidia 3D 2.8 VAT% (quartile 4 vs 2)
VAT% (quartile 1 vs 2)
Recurrence 4.76 (2.94, 13.2)
3.20 (1.77, 10.0)
Pathologic stage, nuclear grade,
histologic subtype, age, ECOG
PS, comorbid conditions
(diabetes, hypertension, end-
stage renal disease), smoking
status
Lee, 2015, Korea [36] 1,738 localized T1-2, N0, M0
(71 deaths, 42 RCC deaths)
449 advanced T3-4, any N and
M (157 deaths, 148 RCC
deaths)
PN or RN from 1994–2012
Median 42 mo (IQR 20-65) Preoperative (6
wk prior to
surgery)
Umbilicus, Xelis CT VAT (< vs median; 117 cm2
for M, 79 for F)
OM all
CSM all
OM T1-2
CSM T1-2
OM T3-4
CSM T3-4
1.65 (1.11, 2.46)
1.67 (1.07, 2.60)
1.10 (0.57, 2.15)
0.96 (0.40, 2.31)
2.22 (1.31, 3.76)
2.19 (1.28, 3.77)
Age, sex, ASA score, type of
nephrectomy, Fuhrman grade,
sarcomatoid component, VAT/
SAT, BMI
Psutka, 2015, USA [37] 387 localized pT1-pT4 RCC
(137 progression, 168 deaths,
80 RCC deaths)
RN from 2000–2010
Median 7.2 y Preoperative (30
d prior to surgery)
L3, Slice-O-Matic SMI (< vs 55 cm2/m2 for M,
39 for F)b
SMI (continuous, cm2/m2)
OM
CSM
Progression
OM
CSM
Progression
1.48 (1.02, 2.15)
1.70 (1.01, 2.85)
1.10 (0.74, 1.63)
0.98 (0.97, 0.997)
0.98 (0.96, 0.999)
1.00 (0.98, 1.01)
Age, sex*, symptoms, CCI,
smoking status, ECOG PS*,
tumour size*, primary tumour
classification, pN*, nuclear
grade, tumour necrosis (*only
for OM)
Peyton, 2016, USA [23] 128 Stage III–IV RCC patients
(54 deaths)
RN from 2008–2012
Median 48.3 mo (range
0.1-78.7)
Preoperative (60
d prior to surgery)c
L3, Philips iSite PACS Total psoas ( vs > Q1;
4.271 cm2/m2 for M, 3.804
for F)
OM 1.77 (0.88, 4.04) Univariable
Thiel, 2016, USA [40] 405 localized pT1-pT4 RCC
patients (45 progression)
Median 4.0 y (range 0.0-
10.3)
Preoperativec Renal vein, software not
reported
Perinephric fat MAP score
(4-5 vs 0-3)d
Progression 2.16 (1.15, 4.06)
2.20 (1.07, 4.52)
Age at surgery
Age at surgery, BMI
248 localized cRCC patients 1.51 (0.70, 3.27) Age at surgery, SSIGN score
287 pT1 RCC patients
(14 progression)
3.46 (1.06, 11.24)
1.89 (0.48, 7.46)
Age at surgery
Age at surgery, BMI, tumour
size
177 pT1 ccRCC patients
(7 progression)
0.93 (0.17, 4.96) Age at surgery, BMI, SSIGN
score
PN or RN from 2002–2014
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Table 4 (Continued )
First author, yr, country (ref) Study population Follow-up Timing of CT scan Level of analysis, image
software used
Tissue
(comparison)
Outcome HR (95% CI) Adjustment factors
Metastatic RCC
Ladoire, 2011, France [29] 59 mRCC patients treated
with first-line antiangiogenic
agents
Median 35.7 mo Pretreatment Umbilicus, ImageJ Antiangiogenic agents:
VAT (> vs median; 133 cm2)
SAT (> vs median; 180 cm2)
Progression
OM
Progression, OM
3.22 (1.60, 6.50)
6.26 (2.29, 17.08)
NS
Nephrectomy, LDH
MSKCC score
46 mRCC patients treated
with cytokines from 2001–
2009
Cytokines:
VAT, SAT Progression, OM NS
Steffens, 2011, Germany [30] 77 mRCC patients treated
with first-line antiangiogenic
agents from 2005–2010
Median 21 mo Pretreatment Umbilicus, ImageJ VAT (< vs  median)
SAT (< vs  median)
Progression
OM
Progression
OM
3.26 (1.39, 7.62)
2.97 (1.36, 6.47)
2.66 (1.24, 5.69)
3.41 (1.61, 7.25)
Age, sex, histological subtype,
MSKCC score
Antoun, 2013, France [31] 142 mRCC patients treated
with targeted therapy
(sunitinib, sorafenib, mTOR
inhibitor)
Median OS 21.4 mo Pretreatment (28
d before initiation)
L3, Slice-O-Matic VAT (< vs  median; 153 cm2
for M and 44 for F)a
OM 1.22 (0.85, 1.78)
0.98 (0.70, 1.36)
Heng score, active treatment
(for progression only)
SAT (< vs  median; 157 cm2
for M and 160 for F)a
OM
Progression or death
1.22 (0.84, 1.77)
1.13 (0.81, 1.57)
SMI (< vs  median; 53 cm2
for M and 37 for F)a
OM
Progression or death
1.34 (0.92, 1.95)
1.18 (0.85, 1.65)
SMD (< vs  median; 38 HU
for M and 36 for F)
OM
Progression or death
1.9 (1.3, 2.9)
2.0 (1.3, 2.9)
Gu, 2015, China [35] 124 mRCC patients
(67 deaths) treated with
targeted therapy from 2008–
2012
Median 30.8 mo Pretreatment L3, ImageJ VATI (continuous, cm2/m2) OM 0.98 (0.97, 0.99) Heng score, age, sex
SATI (continuous, cm2/m2) 0.99 (0.97, 1.00)
SMI (continuous, cm2/m2) 1.00 (0.96, 1.00)
SMD (continuous, HU) 1.00 (0.99, 1.01)
VATI (< vs 33.3 cm2/m2 for
M,  17.7 for F)
2.09 (1.22, 3.57) KPS, time from diagnosis to
treatment, hemoglobin,
Calcium, neutrophil count,
platelet count
VAT (< vs  median; 124 cm2
for M and 98 for F)a
1.93 (1.12, 3.30) Heng score, age
SMI (< vs  median; 48.3 cm2
for M and 39.2 for F)a
1.01 (0.57, 1.76)
SMD (< vs  median; 8.9 HU
for M and 8.0 for F)a
1.14 (0.69, 1.88)
Median OS 24.7 mo
Sharma, 2015, USA [21] 93 mRCC patients (71 deaths)
treated with CN from 2001–
2014
Median 13 mo (IQR 5–31) Preoperative (90
d prior to surgery)c
L3, AW Server Software SMI (< vs  43 cm2/m2 for M
with BMI < 25,  53 for M
with BMI > 25,  41 for F)e
OM 2.127 (1.153, 3.924) BMI, ECOG PS, CCI, albumin,
Heng score, cT, number of
metastatic sites, (neo)adjuvant
systemic therapy
Fukushima, 2016, Japan [38] 92 mRCC patients (52 deaths)
treated with antiangiogenic
agents (33%) or cytokines
(47%) from 2003–2014
Median 19 mo (range 1–
142 mo)
At diagnosis of
mRCC
L3, OsiriX SMI (< vs 43 cm2/m2 for M
with BMI < 25, 5 3 for M
with BMI > 25,  41 for F)e
OM 2.58 (1.20, 6.05) Prior nephrectomy, no. of
metastatic sites, corrected
calcium, LDH
SMD (< vs  41 HU for BMI <
25,  31 for BMI > 25)a
OM 1.48 (0.85, 2.61) MSKCC score
Fukushima, 2016, Japan [39] 37 mRCC patients (16 deaths)
treated with CN from 2003–
2015
Median OS 51 mo Preoperative (1
mo prior to
surgery) and
postoperative (5–6
mo after CN)
L3, OsiriX SMI (< vs 43 cm2/m2 for M
with BMI < 25,  53 for M
with BMI > 25,  41 for F)e
OM 0.86 (0.34, 2.15)f Univariable
SMI stabilized vs decreased OM 0.07 (0.01, 0.25) Preoperative CRP
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3.4. Body composition and perioperative outcomes
For studies on perioperative outcomes [8,9,16–24]
(Table 2), no meta-analysis could be performed due to
heterogeneity in body composition parameters, outcomes,
and effect estimates. Results of studies are described below.
3.4.1. Visceral fat
Three studies investigated VAT in patients treated with
radical [8,22] or partial [9] nephrectomy. Two studies
reported that high versus low VAT cross-sectional area was
associated with longer operation time [8,22], one of them
only showing this for nonexpert surgeons and not for expert
surgeons [22]. One study found that VAT thickness was not
associated with operation time, complications, and esti-
mated blood loss [9].
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Fig. 2 – Two pT1a RCC patients with identical BMI but different body
composition. Main panels: total lumbar CT images (at 3rd lumbar
vertebra level); radiodensity ranges used for skeletal muscle (SM),
S29 to +150 Hounsfield Units (HU); visceral adipose tissue (VAT),
S150 to S50 HU; subcutaneous adipose tissue (SAT), S190 to
S30 HU; and intermuscular adipose tissue (IMAT), S190 to S30 HU.
Insets: psoas and paraspinal muscles: radiodensity ranges used for
normal radiodensity SM, +30 to +150 HU; abnormal (reduced)
radiodensity in two range [ S29 to 0 HU; +1 to +29 HU]; and IMAT,
S190 to S30 HU. The patient in the upper panel is a female aged 78
y with BMI 33.5 kg/m2; SMI = 48.7 cm2/m2; SMD = 24.1 HU;
VAT = 165.5 cm2; SAT = 295.4 cm2; IMAT = 16.2 cm2. The patient in the
lower panel is a female aged 76 y with BMI 33.5 kg/m2; SMI = 34.9 cm2/
m2; SMD = 11.9 HU; VAT = 369.8 cm2; SAT = 252.4 cm2; IMAT = 50.8 cm2.
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3.4.2. Perinephric fat
Six studies assessed perinephric fat thickness [9,16–19,24]
and one study investigated perinephric fat radiodensity [20]
in patients treated with partial [9,16,18–20,24] or radical
nephrectomy [17]. Perinephric fat thickness was positively
associated with operation time in three [17,19,24] of six
studies [9,16–19,24], with estimated blood loss in two
[17,19] of five studies [9,16,17,19,24], andwith increased risk
of complications in one [18] of four studies [9,16,18,24]. No
associations with length of hospital stay [16,18,24] and
warm ischemia time [16,24] were found. Perinephric fat
density was positively correlated with operation time, but
not with estimated blood loss and warm ischemia time [20].
3.4.3. Subcutaneous fat
Three studies investigated SAT thickness in patients treated
with partial nephrectomy [9,18,19]. No significant associa-
tions with perioperative outcomes were reported.
3.4.4. Skeletal muscle
Two studies assessed skeletal muscle in patients treated
with radical [23] or cytoreductive [21] nephrectomy. Low
versus high psoas index was associated with Clavien Grade
III or higher complications, but not with rate of blood
transfusions or length of hospital stay in Stage III–IV
patients [23]. Low versus high SMI was associated with a
higher rate of blood transfusions and a longer length of
hospital stay in mRCC patients [21]. No differences in
complications or estimated blood loss were found.
3.5. Body composition and survival outcomes
For studies on survival outcomes (Table 4), nometa-analysis
could be performed for localized RCC due to the limited
number of studies and heterogeneity in body composition
parameters and outcomes [23,28,32–34,36,37,40]. For
mRCC, no meta-analysis could be performed for VAT and
SAT [29–31,35] because risk estimates based on sex-specific
cut-offs could not be retrieved from some authors
[29,30]. Results of studies are described below.
3.5.1. Visceral fat
Five studies investigated VAT in patientswith localized and/
or advanced disease [28,32–34,36], four of them in Asian
patients [28,32,34,36]. In two studies, low versus high VAT
[32] and both the lowest and the highest versus the second
quartile of the VAT/total adipose tissue ratio [34] were
associated with a higher risk of recurrence in pT1–pT2
[(Fig._3)TD$FIG]
Fig. 3 – Forest plots assessing (A) the risk difference for low versus high skeletal muscle index and dose-limiting toxicity, and the association of low
versus high (B) skeletal muscle index and (C) skeletal muscle radiodensity with overall mortality in metastatic renal cell cancer.
CI = confidence interval; df = difference; IV = inverse variance; MH = Mantel-Henszel; SE = standard error.
E U RO P E AN URO LOG Y F O CU S 4 ( 2 0 1 8 ) 4 2 0 – 4 3 4430
patients. In two studies, low versus high VATwas associated
with higher risk of overall [36] and cancer-specificmortality
[28,36] in Stage I–IV patients. This association was
restricted to Stage III–IV patients [28] and T3–4 patients
[36]. In a US study of Stage I–III patients, median VAT was
much higher than in the Asian studies and no association
with overall mortality was found [33].
Four studies assessed VAT in metastatic patients, part of
them treated with antiangiogenic agents [29–31,35]. Two
studies showed that low versus high VATwas independently
associated with increased risk of progression [30] or overall
mortality [30,35]. In contrast, another study reported that
high versus lowVATwas associatedwith an increased risk of
progression and overall mortality [29], whereas one study
did not find any significant associations [31].
3.5.2. Perinephric fat
One study investigated the Mayo Adhesive Probability
score, derived from perinephric fat thickness and stranding,
in relation to progression in localized RCC. High versus low
Mayo Adhesive Probability score was associated with
higher risk of progression, but this association was no
longer significant after adjustment for tumor size or the
Stage Size Grade and Necrosis score [40].
3.5.3. Subcutaneous fat
One study investigated SAT in Stage I–III patients and found
no association with overall mortality [33]. Four studies
assessed SAT in mRCC [29–31,35], with one study showing
that low versus high SAT was associated with increased risk
of progression and overall mortality [30] and three studies
reporting no significant associations [29,31,35].
3.5.4. Skeletal muscle
Two studies investigated skeletal muscle among patients
with localized disease [23,37]. One study showed that low
versus high SMI was associated with increased risk of
overall and cancer-specific mortality in localized pT1-pT4
patients [37]. Another study found that low versus high
total psoas index was associated with increased risk of
overall mortality in Stage III–IV patients [23]. However, this
result did not reach statistical significance.
3.6. Discussion
This is the first systematic review summarizing the
association of body composition features with clinical
outcomes in RCC patients. Notwithstanding some variation
inmethods and low tomoderate study quality,we found that
mRCC patients with low versus high SMI experienced more
dose-limiting toxicities. We also found that mRCC patients
with low versus high SMI and SMD were at increased risk of
overall mortality. Low versus high VAT and perinephric fat
were associated with better perioperative outcomes and
worse survival in some studies, but results of studies were
inconsistent. No associations for SAT were found.
Up to this decade, studies on body composition in
relation to clinical outcomes have mainly relied on BMI.
However, BMI cannot differentiate between muscle and fat.
Although several studies found that high BMI was
associated with worse perioperative outcomes and better
survival outcomes, results of studies thus far are inconsis-
tent [44–46]. With advances in image-based technologies
such as CT,more specific evaluation ofmuscle and fat is now
possible.
We found that low versus high SMI was associated with
an increased risk of dose-limiting toxicity of antiangiogenic
drugs. This may be explained by alterations in pharmacoki-
netics, including area under the time concentration curve
and clearance. Because antiangiogenic drugs are generally
administered as a fixed dose, thismay result in a higher dose
per kg lean tissue [12,47]. However, further pharmacody-
namic and pharmacokinetic studies are needed tomore fully
characterize the association of drug metabolism and
pharmacokinetics with lean and also fat tissue [47,48].
We also found that low versus high SMI and SMD were
associated with increased risk of overall mortality. This may
be explained by depletion of body protein reserves [49] and
the fact that low SMD is related to high muscle lipid content
and to a propensity for postoperative inflammation
[11]. SMD is a relatively newly characterized and distinctive
abnormality in cancer patients [11]. Given the limited
number of studies to date, its relationship with RCC
outcomes needs to be further explored.
Some studies showed that low versus high VAT and
perinephric fat were associated with better perioperative
outcomes but worse survival outcomes. For example, few
studies reported longer operation times with higher VAT or
perinephric fat [8,17,19]. An explanation may be that
perinephric fat thickness is associated with the presence of
so-called sticky fat, which can limit mobilization of the
kidney and isolation of the tumor [50]. Higher VAT or
perinephric fat may also reduce the perioperative visual
field and operating space [8,9]. With respect to survival
outcomes, high VAT may be beneficial or a marker in terms
of physiological reserves in mRCC. However, other studies
did not find any significant associations or inverse
associations for VAT and perinephric fat. Therefore, it
remains to be determined whether VAT and perinephric fat
are associated with clinical outcomes in patients with
localized and mRCC.
Major strengths of this review include a comprehensive
search strategy, no restriction of the search to specific body
composition parameters or clinical outcomes, and critical
and thorough quality appraisal of included studies. A
systematic review depends on the validity of the included
studies to draw accurate conclusions. Therefore, a key
limitation of our review is the low to moderate quality of
the included studies. Almost all studies were single center
historical cohort studies which may suffer from inherent
limitations such as incomplete collection of CT scans and
incomplete or low quality information on potential con-
founders. Protocols for CT body composition analysis were
heterogeneous. Some studies used different body composi-
tion parameters (eg, thickness or percentage instead of
cross-sectional areas) and their results are not directly
comparable. The use of different anatomical landmarks
(eg, umbilicus or renal vein instead of L3) is likely to be less
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important due to the conversion of continuous cross-
sectional areas to binary data by most studies. Only part
of the studies used sex-specific cut-offs which were either
based on study-specific medians [31,33,35,36] or cut-off
values from the literature [5,21,25–27,37–39]. Some Asian
studies used sex-specific cut-off values for SMI and SMD that
were determined in Caucasian populations, but have not
been validated in Asian populations [27,38,39]. This may
explain some of the discrepant results between studies;Men
are known to have higher VAT, lower SAT and higher SM
mass compared to women [43]. Asians are known to have
higher VAT, higher SAT but lower SM compared with
Caucasians for the sameBMI [51]. Furthermore,most studies
only assessed VAT or SMI, while it is of interest to investigate
these in combination since particularly high VAT in
combination with low SMI may adversely influence survival
[47]. Although most studies adjusted their analyses for
tumor size or stage or were restricted to one tumor stage,
adjustment for prognostic scores was done in about two
thirds of the studies. Hardly any studies had sufficient
follow-up time for survival outcomes or reported complete-
ness of follow-up. Some studies combined RCC patients with
localized, advanced, and metastatic disease. Most studies
had a limited number of patients and/or outcomes,
restricting the statistical power to detect an association.
Future studies are recommended to use a commonly used
and validated protocol at L3 for body composition analysis of
CT scans. They should preferably use a prospective study
design with sufficient follow-up time. CT scans completed
within 30 d prior to start of treatment are deemed to
accurately represent body composition at presentation. VAT
and SMI should be investigated in combination and sex-
specific and race-specific cut-off points should be taken into
account. Sample sizes should be sufficient to differentiate
between localized and advanced and/or metastatic disease.
To assess whether body composition is independently
associated with clinical outcomes, information should be
collected on and statistical analyses should be adjusted for
relevant predictive scores, BMI and other factors related to
the metabolic syndrome, and other potential confounders.
Since some studies suggest that preoperative unintentional
weight loss [46] and postoperative decrease in SMI [39] are
also associated with increased risk of mortality in RCC,
assessing changes in body composition using multiple CT
scanswould be of interest. Three studies inmRCC found that
addition of VAT [35] or SMD [31] to the Heng model or the
integration of SMI into the Memorial Sloan Kettering Cancer
Center risk model [38] could improve the predictive
accuracy of these models. Future studies should investigate
whether body composition features have indeed potential to
improve prediction models for operative and treatment
planning and survival.
4. Conclusions
This systematic review showed that low SMI is associated
with increased dose-limiting toxicity, and that low SMI and
SMD are associated with increased overall mortality in
mRCC. The association of VAT and perinephric fat with
clinical outcomes is inconsistent. No associations for SAT
were found. Larger, preferably prospective studies, asses-
sing all body composition features in combination using a
validated protocol and also focusing on localized RCC, are
needed. They should confirm these findings and investigate
their potential to improve the currently available prediction
models for RCC.
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